Vertex Pharmaceuticals: Earnings Estimates and Zacks Rank Analysis

Vertex Pharmaceuticals (VRTX) has returned -6.2% over the past month, compared to the Zacks S&P 500 composite's -3.7% change. The Zacks Medical - Biomedical and Genetics industry has lost 7.8% over this period. Analysts expect Vertex to post earnings of $4.43 per share for the current quarter, a change of +9.1% from the year-ago quarter. The consensus earnings estimate for the current fiscal year is $19.13, indicating a year-over-year change of +4%. The company has a Zacks Rank #3 (Hold) due to changes in earnings estimate revisions and other factors.